

IPBF FACT SHEET

KETAMINE ABUSE AND THE URINARY TRACT

KETAMINE CYSTITIS

WHAT IS KETAMINE

Ketamine is a dissociative anaesthetic developed in the mid 1960s and is used in human and veterinary medicine. In medical settings, administration of ketamine may be intravenous, subcutaneous, intramuscular, oral, topical intranasal or sublingual. It is used for inducing and maintaining anaesthesia, for analgesia in a variety of pain settings, and as a rapid effect antidepressant. It is perhaps best known for its use in treating injured soldiers during the Vietnam War. Reported side effects in some patients have included hallucinations, nightmares, sedation, dizziness, blurred vision, agitation and nausea/vomiting. It may increase blood pressure and heart rate.

RECREATIONAL ABUSE

Nonmedical (illicit) use was first documented in the late sixties/early seventies when it was emerging as a club drug. By the nineties, ketamine abuse was rapidly increasing in East Asia, particularly in the dance culture of Hong Kong, while today it is being used recreationally worldwide due to its relative low cost compared to similar drugs. As a party drug, it is being used by young people, including very young teenagers. It may be snorted, injected or taken orally in pill form, sometimes masquerading as XTC pills. It may also be mixed with other drugs and of course accompanied by a lot of alcohol. Since ketamine is tasteless and odourless, it can be placed in drinks without the intended victim suspecting and as such is used as a “date rape drug”. The numerous street names for ketamine include K, Special K, Vitamin K, Super Acid, Super C, Bump, Cat Valium, Green K, Honey Oil, Special La Coke, Ket, Kitty, Kit Kat, New Ecstasy, Purple and Jet. A mixture of ketamine and cocaine is called Calvin Klein or CK1. In Hong Kong, the street name is Kai-Jai.

EFFECTS OF KETAMINE ABUSE

Effects associated with recreational ketamine abuse include a hallucinogenic-like effect, a pleasant dream-like state, sense of floating and being separated from your body. However, some ketamine “bad trips” can cause a frightening sensation of total dissociation compared to a near-death experience and known as the “K-hole”, with the sensation of being in a dark tunnel. In addition to the side effects mentioned above, ketamine abuse may also cause amnesia, flashbacks, memory impairment, anxiety, impaired motor function, respiratory and gastrointestinal disorders.

In the past decade, there has been increasing realisation that ketamine abuse can lead to multiple system damage including pain and damage to the urinary tract, with interstitial cystitis-like inflammatory bladder changes and symptoms, with an increased urge to urinate, blood in the urine, incontinence and pain on urination.

CLINICAL PRESENTATION

Since patients may present with IC-like symptoms, young people especially should therefore be questioned regarding the possibility of recreational ketamine abuse. Recent studies in different parts of the world have reported chronic inflammation, often severe lesions without malignancy, denuded epithelium, thickened bladder wall, contracted bladder, reduced bladder capacity, ureteric wall thickening, narrowing and strictures, swollen kidneys. Many patients also experience severe sexual dysfunction. Symptoms have a major impact on the quality of life of this predominantly young group of patients. Symptoms occur after a period of intensive use and may be irreversible. The longer the drug abuse, the worse the risk of extensive and devastating damage.

TREATMENT

Complete cessation of ketamine abuse is essential to reduce symptoms. Cessation is difficult for most patients due to both the psychological addiction and the pain killing effect of ketamine on their symptoms. It is crucial to treat patients in the acute phase with symptomatic medication for their pain and overactive bladder symptoms. Treatment should be combined with addiction therapy for the best outcome. If complete abstinence is reached at an early phase, many patients can recover from their symptoms. Some patients have extensive irreversible damage and can be treated with different modalities such as intravesical sodium hyaluronate or chondroitin sulfate, botulinum toxin injections, intravesical coagulation of ulceration or hydrodistension. In some cases, a partial cystectomy with bladder augmentation is needed. Last resort treatment, especially for the group of patients who are not able to achieve abstinence due to their pain symptoms, a cystectomy with urinary diversion is sometimes necessary.

During the diagnostic work-up of these patients, it is important to check the upper urinary tract with ultrasound and blood tests, because of a 10% risk of involvement.

PREVALENCE

Prevalence of urinary tract symptoms among ketamine abusers is uncertain, but studies have indicated that at least between a quarter and one third of ketamine abusers may be affected.

AWARENESS

It is vital to raise awareness and to warn teenagers and young adults of the risks. It is equally essential to increase awareness among health practitioners since delays in diagnosis can lead to irreversible pathological changes among ketamine abusers. Furthermore, if ketamine abuse continues to escalate, the resultant urinary tract symptoms could place high demands on health resources at substantial cost in the future.

References and further reading:

- Belal M, Downey A, Doherty R, Ali A, Hashim H, Kozan A, Kujawa M, Pakzad M, Rashid T, Osman N, Sahai A, Biers S; BAUS Section of Female, Neurological and Urodynamic Urology. British Association of Urological Surgeons Consensus statements on the management of ketamine uropathy. *BJU Int.* 2024 May 22. doi: 10.1111/bju.16404. Epub ahead of print. PMID: 38778743.
- Jhang JF, Birder LA, Kuo HC. Pathophysiology, clinical presentation, and management of ketamine-induced cystitis. *Tzu Chi Med J.* 2023 Jun 13;35(3):205-212. doi: 10.4103/tcmj.tcmj_94_23. PMID: 37545795; PMCID: PMC10399845. (open access)
- Vizgan G, Huamán M, Rychik K, Edeson M, Blaivas JG. Ketamine-induced uropathy: A narrative systemic review of surgical outcomes of reconstructive surgery. *BJUI Compass.* 2023 Apr 19;4(4):377-384. doi: 10.1002/bco2.239. PMID: 37334018; PMCID: PMC10268589. (open access)
- Zhou J, Scott C, Miab ZR, Lehmann C. Current approaches for the treatment of ketamine-induced cystitis. *Neurourol Urodyn.* 2023 Mar;42(3):680-689. doi: 10.1002/nau.25148. Epub 2023 Feb 13. PMID: 36780131.
- Orhurhu VJ, Vashisht R, Claus LE, Cohen SP. Ketamine Toxicity. 2023 Jan 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan—. PMID: 31082131. (Free at <https://www.ncbi.nlm.nih.gov/books/NBK541087/>)
- Chan EOT, Chan VWS, Tang TST, Cheung V, Wong MCS, Yee CH, Ng CF, Teoh JYC. Systematic review and meta-analysis of ketamine-associated uropathy. *Hong Kong Med J.* 2022 Dec;28(6):466-474. doi: 10.12809/hkmj209194. Epub 2022 Dec 5. PMID: 36464318. (open access)

- Anderson DJ, Zhou J, Cao D, McDonald M, Guenther M, Hasoon J, Viswanath O, Kaye AD, Urits I. Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug. *Health Psychol Res.* 2022 Sep 15;10(3):38247. doi: 10.52965/001c.38247. PMID: 36118982; PMCID: PMC9476224. (open access)
- Lamers G, Van Dyck J, Schapmans S, De Coster K, Mortier D, Zabegalina N. Ketamine-induced uropathy: A diagnostic pitfall in an increasing healthcare issue in youngsters. *Urol Case Rep.* 2022 Feb 1;42:102019. doi: 10.1016/j.eucr.2022.102019. PMID: 35530548; PMCID: PMC9073215. (open access)
- Chen CL, Wu ST, Cha TL, Sun GH, Meng E. Molecular Pathophysiology and Potential Therapeutic Strategies of Ketamine-Related Cystitis. *Biology (Basel).* 2022 Mar 24;11(4):502. doi: 10.3390/biology11040502. PMID: 35453701; PMCID: PMC9029571. (open access)
- Chen CL, Wu ST, Cha TL, Sun GH, Meng E. Molecular Pathophysiology and Potential Therapeutic Strategies of Ketamine-Related Cystitis. *Biology (Basel).* 2022 Mar 24;11(4):502. doi: 10.3390/biology11040502. PMID: 35453701; PMCID: PMC9029571.
- Ou SH, Wu LY, Chen HY, Huang CW, Hsu CY, Chen CL, Chou KJ, Fang HC, Lee PT. Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy. *Int J Environ Res Public Health.* 2020 Oct 4;17(19):7260. doi: 10.3390/ijerph17197260. PMID: 33020445; PMCID: PMC7579140. (open access)
- Castellani D, Pirola GM, Gubbiotti M, Rubilotta E, Gudaru K, Gregori A, Dellabella M. What urologists need to know about ketamine-induced uropathy: A systematic review. *Neurourol Urodyn.* 2020 Apr;39(4):1049-1062. doi: 10.1002/nau.24341. Epub 2020 Mar 25. PMID: 32212278.
- Jhang JF, Wang HJ, Hsu YH, Birder LA, Kuo HC. Upregulation of neurotrophins and transforming growth factor- β expression in the bladder may lead to nerve hyperplasia and fibrosis in patients with severe ketamine-associated cystitis. *Neurourol Urodyn.* 2019 Nov;38(8):2303-2310. doi: 10.1002/nau.24139. Epub 2019 Aug 21. PMID: 31433072.
- Jhang JF, Birder LA, Chancellor MB, Kuo HC. Patient characteristics for different therapeutic strategies in the management ketamine cystitis. *Neurourol Urodyn.* 2017 Mar;36(3):687-691. doi: 10.1002/nau.22996. Epub 2016 Mar 21.
- Yek J, Sundaram P, Aydin H, Kuo T, Ng LG. The clinical presentation and diagnosis of ketamine-associated urinary tract dysfunction in Singapore. *Singapore Med J.* 2015 Dec;56(12):660-4; quiz 665. doi: 10.11622/smedj.2015185. Free PMC Article.
- Myers FA Jr, Bluth MH, Cheung WW. Ketamine: A Cause of Urinary Tract Dysfunction. *Clin Lab Med.* 2016 Dec;36(4):721-744. doi: 10.1016/j.cll.2016.07.008.
- Sassano-Higgins S, Baron D, Juarez G, Esmaili N, Gold M. A review of ketamine abuse and diversion. *Depress Anxiety.* 2016 Aug;33(8):718-27. doi: 10.1002/da.22536. Epub 2016 Jun 22.

Contact and further information: info@painful-bladder.org

The International Painful Bladder Foundation does not engage in the practice of medicine. It is not a medical authority nor does it claim to have medical knowledge. The IPBF endeavours to ensure that all information it provides is correct and accurate but does not accept any liability for errors or inaccuracies.

The International Painful Bladder Foundation is a non-profit voluntary foundation registered at the Chamber of Commerce Rotterdam, the Netherlands under number: 24382693.